JP2016514689A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514689A5 JP2016514689A5 JP2016503092A JP2016503092A JP2016514689A5 JP 2016514689 A5 JP2016514689 A5 JP 2016514689A5 JP 2016503092 A JP2016503092 A JP 2016503092A JP 2016503092 A JP2016503092 A JP 2016503092A JP 2016514689 A5 JP2016514689 A5 JP 2016514689A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- chemotherapeutic agent
- composition according
- cancer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YOWAPKICKYMWFY-UHFFFAOYSA-N CC(C)(CN(CC1)c(cc2)cnc2Nc2ncc(cc3[n]4C5(CCCCC5)CNC3=O)c4n2)N1C1CC1 Chemical compound CC(C)(CN(CC1)c(cc2)cnc2Nc2ncc(cc3[n]4C5(CCCCC5)CNC3=O)c4n2)N1C1CC1 YOWAPKICKYMWFY-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798772P | 2013-03-15 | 2013-03-15 | |
| US61/798,772 | 2013-03-15 | ||
| US201361861374P | 2013-08-01 | 2013-08-01 | |
| US61/861,374 | 2013-08-01 | ||
| US201361911354P | 2013-12-03 | 2013-12-03 | |
| US61/911,354 | 2013-12-03 | ||
| US201461949786P | 2014-03-07 | 2014-03-07 | |
| US61/949,786 | 2014-03-07 | ||
| PCT/US2014/029429 WO2014144847A2 (en) | 2013-03-15 | 2014-03-14 | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018089382A Division JP6517401B2 (ja) | 2013-03-15 | 2018-05-07 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016514689A JP2016514689A (ja) | 2016-05-23 |
| JP2016514689A5 true JP2016514689A5 (OSRAM) | 2017-04-20 |
| JP6337083B2 JP6337083B2 (ja) | 2018-06-06 |
Family
ID=51527871
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502870A Active JP6430483B2 (ja) | 2013-03-15 | 2014-03-14 | 化学療法の間の正常細胞の一時的な保護 |
| JP2016503092A Active JP6337083B2 (ja) | 2013-03-15 | 2014-03-14 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
| JP2018089382A Active JP6517401B2 (ja) | 2013-03-15 | 2018-05-07 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
| JP2018204234A Active JP6767456B2 (ja) | 2013-03-15 | 2018-10-30 | 化学療法の間の正常細胞の一時的な保護 |
| JP2019077828A Active JP6738933B6 (ja) | 2013-03-15 | 2019-04-16 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
| JP2020123189A Active JP7250737B2 (ja) | 2013-03-15 | 2020-07-17 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
| JP2020155691A Active JP7213854B2 (ja) | 2013-03-15 | 2020-09-16 | 化学療法の間の正常細胞の一時的な保護 |
| JP2023005413A Ceased JP2023052449A (ja) | 2013-03-15 | 2023-01-17 | 化学療法の間の正常細胞の一時的な保護 |
| JP2023044746A Withdrawn JP2023078341A (ja) | 2013-03-15 | 2023-03-20 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502870A Active JP6430483B2 (ja) | 2013-03-15 | 2014-03-14 | 化学療法の間の正常細胞の一時的な保護 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018089382A Active JP6517401B2 (ja) | 2013-03-15 | 2018-05-07 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
| JP2018204234A Active JP6767456B2 (ja) | 2013-03-15 | 2018-10-30 | 化学療法の間の正常細胞の一時的な保護 |
| JP2019077828A Active JP6738933B6 (ja) | 2013-03-15 | 2019-04-16 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
| JP2020123189A Active JP7250737B2 (ja) | 2013-03-15 | 2020-07-17 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
| JP2020155691A Active JP7213854B2 (ja) | 2013-03-15 | 2020-09-16 | 化学療法の間の正常細胞の一時的な保護 |
| JP2023005413A Ceased JP2023052449A (ja) | 2013-03-15 | 2023-01-17 | 化学療法の間の正常細胞の一時的な保護 |
| JP2023044746A Withdrawn JP2023078341A (ja) | 2013-03-15 | 2023-03-20 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
Country Status (18)
| Country | Link |
|---|---|
| US (15) | US9527857B2 (OSRAM) |
| EP (4) | EP2968291B1 (OSRAM) |
| JP (9) | JP6430483B2 (OSRAM) |
| CN (4) | CN108434149B (OSRAM) |
| CA (2) | CA2906166C (OSRAM) |
| CY (1) | CY1122434T1 (OSRAM) |
| DK (1) | DK2968290T3 (OSRAM) |
| ES (2) | ES2761406T3 (OSRAM) |
| HR (1) | HRP20192168T1 (OSRAM) |
| HU (1) | HUE046653T2 (OSRAM) |
| LT (1) | LT2968290T (OSRAM) |
| ME (1) | ME03557B (OSRAM) |
| PL (1) | PL2968290T3 (OSRAM) |
| PT (1) | PT2968290T (OSRAM) |
| RS (1) | RS59790B1 (OSRAM) |
| SI (1) | SI2968290T1 (OSRAM) |
| SM (1) | SMT201900681T1 (OSRAM) |
| WO (2) | WO2014144326A1 (OSRAM) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009061345A2 (en) | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Targeting cdk4 and cdk6 in cancer therapy |
| US8691830B2 (en) * | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| EP2831080B1 (en) | 2012-03-29 | 2017-03-15 | Francis Xavier Tavares | Lactam kinase inhibitors |
| CA2870019C (en) | 2012-04-26 | 2020-08-18 | Francis Xavier Tavares | Synthesis of lactams |
| EP2967050A4 (en) | 2013-03-15 | 2016-09-28 | G1 Therapeutics Inc | HIGH-ACTIVE ANTINEOPLASTIC AND ANTIPROLIFERATIVE AGENTS |
| EP2968291B1 (en) * | 2013-03-15 | 2025-04-16 | Pharmacosmos Holding A/S | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| US9717735B2 (en) | 2014-04-17 | 2017-08-01 | G1 Therapeutics, Inc. | Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| WO2016040858A1 (en) * | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016126889A1 (en) * | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| HUE051898T2 (hu) * | 2015-06-17 | 2021-03-29 | Pfizer | Triciklusos vegyületek és alkalmazásuk foszfodiészteráz inhibitorokként |
| EP3340986A1 (en) * | 2015-08-28 | 2018-07-04 | Novartis AG | A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer |
| JP6635374B2 (ja) * | 2015-12-18 | 2020-01-22 | 京都府公立大学法人 | 癌におけるリン酸化ｒｂタンパク質を指標としたイリノテカン感受性予測法 |
| WO2017161253A1 (en) * | 2016-03-18 | 2017-09-21 | Tufts Medical Center | Compositions and methods for treating and preventing metabolic disorders |
| CN114539273A (zh) | 2016-06-07 | 2022-05-27 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| AU2017290362B2 (en) * | 2016-07-01 | 2021-08-05 | Pharmacosmos Holding A/S | Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines |
| WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| CA3028751A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| RU2769251C2 (ru) | 2016-08-23 | 2022-03-29 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Комбинированная терапия для лечения гепатоцеллюлярной карциномы |
| WO2018089518A1 (en) | 2016-11-08 | 2018-05-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods of modulating anti-tumor immunity |
| KR20240023677A (ko) | 2016-12-05 | 2024-02-22 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
| AU2018205262A1 (en) * | 2017-01-06 | 2019-07-11 | G1 Therapeutics, Inc. | Combination therapy for the treatment of cancer |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| EP3585389A4 (en) | 2017-02-22 | 2020-12-23 | G1 Therapeutics, Inc. | EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS |
| BR112019019261A2 (pt) | 2017-03-16 | 2020-06-16 | Eisai R & D Management Co., Ltd. | Terapias de combinação para o tratamento de câncer de mama |
| HRP20241239T1 (hr) | 2017-03-23 | 2024-12-06 | Jacobio Pharmaceuticals Co., Ltd. | Novi heterociklički derivati korisni kao shp2 inhibitori |
| MX392531B (es) | 2017-06-29 | 2025-03-24 | G1 Therapeutics Inc | Formas morficas de g1t38 y metodos de preparacion de las mismas. |
| CN111094291B (zh) * | 2017-08-11 | 2022-06-21 | 晟科药业（江苏）有限公司 | 1h-吡唑并[4,3-h]喹唑啉类化合物作为蛋白激酶抑制剂 |
| WO2019136451A1 (en) | 2018-01-08 | 2019-07-11 | G1 Therapeutics, Inc. | G1t38 superior dosage regimes |
| MA51846A (fr) | 2018-02-15 | 2021-04-21 | Nuvation Bio Inc | Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases |
| CN112218634A (zh) * | 2018-04-09 | 2021-01-12 | G1治疗公司 | 具有驱动致癌突变的癌症的治疗 |
| AU2019310595B2 (en) * | 2018-07-27 | 2022-11-24 | 1200 Pharma Llc | CDK inhibitors and uses thereof |
| CN120817904A (zh) | 2018-08-24 | 2025-10-21 | 法码科思莫斯有限公司 | 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成 |
| WO2020063760A1 (en) | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| WO2020097625A1 (en) * | 2018-11-09 | 2020-05-14 | G1 Therapeutics, Inc. | Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations |
| WO2020206035A1 (en) * | 2019-04-01 | 2020-10-08 | G1 Therapeutics, Inc. | Treatment of cdk4/6 inhibitor resistant neoplastic disorders |
| AU2020296087A1 (en) * | 2019-06-18 | 2022-01-27 | Pharmacosmos Holding A/S | Patient selection for enhancement of anti-tumor immunity in cancer patients |
| TW202128174A (zh) * | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
| ES3048084T3 (en) | 2020-05-19 | 2025-12-09 | Pharmacosmos Holding As | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| AU2021287380A1 (en) * | 2020-06-11 | 2023-01-05 | Lunella Biotech, Inc. | Selective CDK4/6 inhibitor cancer therapeutics |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| CN116157403B (zh) * | 2020-06-15 | 2025-04-25 | 海南先声再明医药股份有限公司 | 曲拉西利的形态及其制造方法 |
| CN113788837B (zh) * | 2021-08-02 | 2022-08-26 | 深圳湾实验室坪山生物医药研发转化中心 | Trilaciclib的合成方法 |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| WO2024116069A1 (en) * | 2022-11-28 | 2024-06-06 | Assia Chemical Industries Ltd. | Novel trilaciclib intermediates, method of preparation and use thereof |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591855A (en) | 1994-10-14 | 1997-01-07 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| ES2301194T3 (es) | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US20040006074A1 (en) | 1998-04-28 | 2004-01-08 | The Government Of The United States Of America | Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer |
| AU778735B2 (en) | 1998-06-16 | 2004-12-16 | Centre National De La Recherche Scientifique | Fused azepinone cyclin dependent kinase inhibitors |
| AU3584200A (en) | 1999-01-29 | 2000-08-18 | Board Of Trustees Of The University Of Illinois, The | P53 inhibitors and therapeutic use of the same |
| US6958333B1 (en) | 1999-07-26 | 2005-10-25 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| US6291504B1 (en) | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
| EP1242420A2 (en) | 1999-12-16 | 2002-09-25 | Eli Lilly And Company | Agents and methods for the treatment of proliferative diseases |
| US7053070B2 (en) | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| CN100351253C (zh) | 2000-06-26 | 2007-11-28 | 辉瑞产品公司 | 作为免疫抑制剂的吡咯并[2,3－d]嘧啶化合物 |
| TR200401316T4 (tr) | 2000-09-29 | 2004-07-21 | Eli Lilly And Company | Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler |
| WO2002044174A2 (en) | 2000-12-01 | 2002-06-06 | Bristol-Myers Squibb Pharma Company | 3-(2,4-dimethylthiazol-5-yl) indeno[1,2-c]pyrazol-4-one derivatives as cdk inhibitors |
| WO2002069892A2 (en) | 2001-02-28 | 2002-09-12 | Temple University Of The Commonwealth System Of Higher Education | METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES |
| JP2004533449A (ja) | 2001-05-11 | 2004-11-04 | ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム | Ｃｄ２６を発現している細胞に関連する疾患の治療としての抗ｃｄ２６モノクローナル抗体 |
| GEP20063909B (en) | 2002-01-22 | 2006-08-25 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES |
| CA2495787A1 (en) | 2002-05-01 | 2003-11-13 | Chromos Molecular Systems, Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
| JP2006516561A (ja) | 2003-01-17 | 2006-07-06 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類 |
| EA010904B1 (ru) | 2003-05-22 | 2008-12-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ |
| ATE412650T1 (de) | 2003-07-11 | 2008-11-15 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| BRPI0415833A (pt) | 2003-10-23 | 2007-01-02 | Hoffmann La Roche | derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos |
| GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
| EP1740184A1 (en) | 2004-03-30 | 2007-01-10 | Pfizer Products Incorporated | Combinations of signal transduction inhibitors |
| WO2005100999A2 (en) | 2004-04-08 | 2005-10-27 | Cornell Research Foundation, Inc. | Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer |
| ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
| WO2005117908A2 (en) | 2004-05-28 | 2005-12-15 | Gemin X Biotechnologies, Inc. | Triheterocyclic compounds compositions, and methods for treating cancer or viral diseases |
| WO2006074985A1 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| US20080161355A1 (en) | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents |
| EP1881983B1 (en) | 2005-05-20 | 2012-01-11 | Vertex Pharmaceuticals, Inc. | Pyrrolopyridines useful as inhibitors of protein kinase |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| ATE448230T1 (de) | 2005-12-09 | 2009-11-15 | Hoffmann La Roche | Für die behandlung von obesitas geeignete tricyclische amidderivate |
| BRPI0620151A2 (pt) | 2005-12-22 | 2010-06-29 | Wyeth Corp | composto; composição farmacêutica; método de tratar ou inibir o crescimento de células tumorais cancerosas em um mamìfero que deste necessita; método; e processo |
| EP2591775A1 (en) | 2006-04-05 | 2013-05-15 | Novartis AG | Combinations comprising mtor inhibitors for treating cancer |
| US20070270362A1 (en) | 2006-05-18 | 2007-11-22 | The University Of Washington | Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders |
| CA2656290A1 (en) | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| EP2061469B8 (en) | 2006-09-11 | 2014-02-26 | Curis, Inc. | Quinazoline based egfr inhibitors |
| AU2007333791A1 (en) | 2006-12-14 | 2008-06-26 | Panacea Pharmaceuticals, Inc. | Methods of neuroprotection by cyclin-dependent kinase inhibition |
| AU2007336933A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections |
| US20110002855A1 (en) | 2007-06-25 | 2011-01-06 | Neurogen Corporation | Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues |
| WO2009061345A2 (en) | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Targeting cdk4 and cdk6 in cancer therapy |
| MX2010006457A (es) | 2007-12-19 | 2010-07-05 | Amgen Inc | Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular. |
| WO2010012777A1 (en) | 2008-07-29 | 2010-02-04 | Nerviano Medical Sciences S.R.L. | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
| CN102186856B (zh) | 2008-08-22 | 2014-09-24 | 诺华股份有限公司 | 作为cdk抑制剂的吡咯并嘧啶化合物 |
| EP2341906A4 (en) * | 2008-10-01 | 2012-06-13 | Univ North Carolina | HEMATOPOIETIC PROTECTION AGAINST IONIZATION RADIATION USING SELF-ACTIVE CYCLINE-DEPENDENT KINASE-4/6-HEMMER |
| AU2009298367A1 (en) | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| EP3406260B1 (en) | 2009-05-13 | 2020-09-23 | The University of North Carolina at Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| WO2011103485A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| FR2957748B1 (fr) * | 2010-03-16 | 2012-09-07 | St Microelectronics Grenoble 2 | Composant electronique a montage en surface |
| CN102299073A (zh) | 2010-06-25 | 2011-12-28 | 无锡华润上华半导体有限公司 | Vdmos器件及其制作方法 |
| SG10201508715YA (en) | 2010-10-25 | 2015-11-27 | G1 Therapeutics Inc | Cdk inhibitors |
| US8691830B2 (en) * | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| DK2635583T3 (en) | 2010-11-02 | 2015-08-03 | Promega Corp | Coelenterazinderivater and methods of use thereof |
| WO2012068381A2 (en) | 2010-11-17 | 2012-05-24 | The University Of North Carolina At Chapel Hill | Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6 |
| EP2655375B1 (fr) | 2010-12-23 | 2014-12-03 | Sanofi | Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique |
| DK2688887T3 (en) | 2011-03-23 | 2015-06-29 | Amgen Inc | DEHYDRATED tricyclic DUALINHIBITORER OF CDK 4/6 AND FLT3 |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| AU2012279117A1 (en) | 2011-07-01 | 2014-01-09 | Novartis Ag | Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer |
| ES2654177T3 (es) | 2011-07-27 | 2018-02-12 | Astrazeneca Ab | Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer |
| EP2831080B1 (en) | 2012-03-29 | 2017-03-15 | Francis Xavier Tavares | Lactam kinase inhibitors |
| CA2870019C (en) | 2012-04-26 | 2020-08-18 | Francis Xavier Tavares | Synthesis of lactams |
| HK1213044A1 (zh) | 2012-08-03 | 2016-06-24 | Foundation Medicine, Inc. | 人乳头瘤病毒作为肿瘤预後的预测因子 |
| US9241941B2 (en) | 2012-09-20 | 2016-01-26 | Memorial Sloan-Kettering Cancer Center | Methods for treatment of lymphomas with mutations in cell cycle genes |
| EP2925365A1 (en) | 2012-11-28 | 2015-10-07 | Novartis AG | Combination therapy |
| US20140274896A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
| EP2967050A4 (en) * | 2013-03-15 | 2016-09-28 | G1 Therapeutics Inc | HIGH-ACTIVE ANTINEOPLASTIC AND ANTIPROLIFERATIVE AGENTS |
| EP2968291B1 (en) * | 2013-03-15 | 2025-04-16 | Pharmacosmos Holding A/S | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| BR112015025711A8 (pt) | 2013-04-08 | 2019-12-17 | Janssen Pharmaceutica Nv | uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer |
| EP3003309B1 (en) | 2013-05-30 | 2020-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2015061407A1 (en) | 2013-10-24 | 2015-04-30 | Francis Xavier Tavares | Process for synthesis of lactams |
| US10314842B2 (en) | 2013-12-02 | 2019-06-11 | Cornell University | Methods for treating B cell proliferative disorders |
| ES2687477T3 (es) | 2013-12-31 | 2018-10-25 | Xuanzhu Pharma Co., Ltd. | Inhibidor de quinasa y su uso |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| US9717735B2 (en) | 2014-04-17 | 2017-08-01 | G1 Therapeutics, Inc. | Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation |
| WO2016040848A1 (en) * | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| WO2016040858A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| US9374037B2 (en) | 2014-10-30 | 2016-06-21 | M/A-Com Technology Solutions Holdings, Inc. | Voltage-controlled oscillator with mask-selectable performance |
| WO2016126889A1 (en) | 2015-02-03 | 2016-08-11 | G1 Therapeutics, Inc. | Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy |
| AU2017290362B2 (en) * | 2016-07-01 | 2021-08-05 | Pharmacosmos Holding A/S | Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| KR20240023677A (ko) * | 2016-12-05 | 2024-02-22 | 쥐원 쎄라퓨틱스, 인크. | 화학요법 레지멘 동안의 면역 반응의 보존 |
| EP3551185A4 (en) * | 2016-12-08 | 2021-07-14 | Icahn School of Medicine at Mount Sinai | COMPOSITIONS AND METHODS OF TREATMENT OF CDK4 / 6 MEDIATED CANCER |
| AU2018205262A1 (en) * | 2017-01-06 | 2019-07-11 | G1 Therapeutics, Inc. | Combination therapy for the treatment of cancer |
| US11395821B2 (en) * | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| EP3580223A4 (en) * | 2017-02-10 | 2021-01-06 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| EP3585389A4 (en) * | 2017-02-22 | 2020-12-23 | G1 Therapeutics, Inc. | EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS |
| MX392531B (es) * | 2017-06-29 | 2025-03-24 | G1 Therapeutics Inc | Formas morficas de g1t38 y metodos de preparacion de las mismas. |
| WO2019136244A1 (en) | 2018-01-04 | 2019-07-11 | G1 Therapeutics, Inc. | Heterocyclic compounds for the treatment of abnormal cellular proliferation |
| WO2019136451A1 (en) * | 2018-01-08 | 2019-07-11 | G1 Therapeutics, Inc. | G1t38 superior dosage regimes |
| CN112218634A (zh) * | 2018-04-09 | 2021-01-12 | G1治疗公司 | 具有驱动致癌突变的癌症的治疗 |
| WO2020023502A1 (en) * | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| AU2020296087A1 (en) * | 2019-06-18 | 2022-01-27 | Pharmacosmos Holding A/S | Patient selection for enhancement of anti-tumor immunity in cancer patients |
| TW202128174A (zh) * | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
-
2014
- 2014-03-14 EP EP14765105.3A patent/EP2968291B1/en active Active
- 2014-03-14 PL PL14762438T patent/PL2968290T3/pl unknown
- 2014-03-14 RS RS20191537A patent/RS59790B1/sr unknown
- 2014-03-14 JP JP2016502870A patent/JP6430483B2/ja active Active
- 2014-03-14 ES ES14762438T patent/ES2761406T3/es active Active
- 2014-03-14 JP JP2016503092A patent/JP6337083B2/ja active Active
- 2014-03-14 CN CN201810443050.5A patent/CN108434149B/zh active Active
- 2014-03-14 US US14/214,048 patent/US9527857B2/en active Active
- 2014-03-14 CA CA2906166A patent/CA2906166C/en active Active
- 2014-03-14 CA CA2906156A patent/CA2906156C/en active Active
- 2014-03-14 WO PCT/US2014/028685 patent/WO2014144326A1/en not_active Ceased
- 2014-03-14 ME MEP-2019-338A patent/ME03557B/me unknown
- 2014-03-14 SI SI201431380T patent/SI2968290T1/sl unknown
- 2014-03-14 SM SM20190681T patent/SMT201900681T1/it unknown
- 2014-03-14 EP EP25170501.8A patent/EP4596051A3/en active Pending
- 2014-03-14 US US14/212,430 patent/US9487530B2/en active Active
- 2014-03-14 EP EP14762438.1A patent/EP2968290B1/en active Active
- 2014-03-14 CN CN201810253672.1A patent/CN108283644B/zh active Active
- 2014-03-14 HU HUE14762438A patent/HUE046653T2/hu unknown
- 2014-03-14 EP EP19198057.2A patent/EP3653209A1/en active Pending
- 2014-03-14 CN CN201480027281.8A patent/CN105473140B/zh active Active
- 2014-03-14 ES ES14765105T patent/ES3032492T3/es active Active
- 2014-03-14 PT PT147624381T patent/PT2968290T/pt unknown
- 2014-03-14 CN CN201480027269.7A patent/CN105407889B/zh active Active
- 2014-03-14 HR HRP20192168TT patent/HRP20192168T1/hr unknown
- 2014-03-14 US US14/212,911 patent/US9464092B2/en active Active
- 2014-03-14 DK DK14762438T patent/DK2968290T3/da active
- 2014-03-14 WO PCT/US2014/029429 patent/WO2014144847A2/en not_active Ceased
- 2014-03-14 LT LT14762438T patent/LT2968290T/lt unknown
-
2016
- 2016-10-07 US US15/288,878 patent/US9931345B2/en active Active
- 2016-11-03 US US15/342,990 patent/US10085992B2/en active Active
- 2016-12-21 US US15/387,083 patent/US10076523B2/en active Active
-
2018
- 2018-04-02 US US15/943,278 patent/US10660896B2/en active Active
- 2018-05-07 JP JP2018089382A patent/JP6517401B2/ja active Active
- 2018-08-24 US US16/112,360 patent/US10966984B2/en active Active
- 2018-08-24 US US16/112,362 patent/US10434104B2/en active Active
- 2018-10-30 JP JP2018204234A patent/JP6767456B2/ja active Active
- 2018-11-01 US US16/178,419 patent/US10925878B2/en active Active
-
2019
- 2019-04-16 JP JP2019077828A patent/JP6738933B6/ja active Active
- 2019-12-11 CY CY20191101306T patent/CY1122434T1/el unknown
-
2020
- 2020-05-28 US US16/886,309 patent/US11040042B2/en active Active
- 2020-07-17 JP JP2020123189A patent/JP7250737B2/ja active Active
- 2020-09-16 JP JP2020155691A patent/JP7213854B2/ja active Active
-
2021
- 2021-02-22 US US17/181,638 patent/US11654148B2/en active Active
- 2021-04-05 US US17/222,873 patent/US11717523B2/en active Active
-
2023
- 2023-01-17 JP JP2023005413A patent/JP2023052449A/ja not_active Ceased
- 2023-03-06 US US18/117,983 patent/US20230364098A1/en active Pending
- 2023-03-20 JP JP2023044746A patent/JP2023078341A/ja not_active Withdrawn
- 2023-08-07 US US18/231,091 patent/US20230381189A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514689A5 (OSRAM) | ||
| JP2019131609A5 (OSRAM) | ||
| Iancu et al. | Tyrosine kinase inhibitors in breast cancer | |
| JP2016538344A5 (OSRAM) | ||
| JP2016501221A5 (OSRAM) | ||
| CN113748114A (zh) | 一种喹唑啉化合物及其在医药上的应用 | |
| JP2017516775A5 (OSRAM) | ||
| Jhaveri et al. | HSP90 inhibitors for cancer therapy and overcoming drug resistance | |
| JP2015512398A5 (OSRAM) | ||
| CN109963842A (zh) | 苯并咪唑类化合物激酶抑制剂及其制备方法和应用 | |
| JP2009501141A5 (ja) | 骨腫瘍の治療のための抗igf-ir抗体 | |
| JP2018504418A5 (OSRAM) | ||
| CN109415770A (zh) | 乳腺癌标志物及应用 | |
| JP2019501204A5 (OSRAM) | ||
| JP2016528246A5 (OSRAM) | ||
| RU2016108667A (ru) | Комбинированная терапия для лечения рака | |
| ME02470B (me) | Nanočesтice nabijene sa hemoterapeutskim anтitumorskim lekom | |
| JP2013520431A5 (OSRAM) | ||
| RU2016112608A (ru) | Лечение рака комбинацией плинабулина и таксана | |
| CN113366008A (zh) | 一种cd73抑制剂，其制备方法和应用 | |
| Li et al. | Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway | |
| RU2020113246A (ru) | Комбинация ингибитора parp и антагониста, связывающегося с осью pd-1 | |
| JP2019510075A5 (OSRAM) | ||
| JP2016531563A5 (OSRAM) | ||
| JP2016540015A5 (OSRAM) |